Pharmaceuticals company Jagsonpal Pharmaceuticals announced Q4FY25 results Revenue: Rs 586 million compared to Rs 435 million during Q4FY24, change 34.7%. EBITDA: Rs 97 million compared to Rs 49 million during Q4FY24, change 96.6%. EBITDA margin: 16.6% for Q4FY25. PAT: Rs 66 million compared to Rs 35 million during Q4FY24, change 85.5%. Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals, said: “We are pleased with our FY25 performance, which underscores the strength of our strategy and execution. Revenue grew 29% to Rs 2,687 million, while operating EBITDA rose 59% to Rs 579 million, driven by a 410 bps margin expansion—reflecting disciplined cost management and successful business integration. Our strategic initiatives are delivering results across key metrics. A major milestone was Indocap® becoming Jagsonpal’s first Rs 50 crore brand (Source: IQVIA), highlighting its strong brand equity. The launch of Indocap® P to further strengthen our leadership in safer pain management. Our Q4FY25 results reaffirm operational alignment, with revenue of Rs586 million (up 35%) and operating EBITDA of Rs 97 million (up 97%). Our key focus now remains on accelerating organic growth even as we continue to evaluate synergistic inorganic opportunities. With strong internal accruals and a healthy balance sheet, we are well-positioned to invest for long-term value creation.” Result PDF